A woman donated her brain so scientists could study a pioneering treatment. A laboratory accidentally threw it out
A children's hospital in Wisconsin said it accidentally disposed of the brain of a young woman that was donated for research. The woman had undergone pioneering gene treatments for a rare degenerative disease, and researchers hoped studying her brain would provide them with invaluable data.
Ashtyn Fellenz died at age 24 on December 5, 2024. As a child, she was diagnosed with Canavan Disease, a rare genetic disorder that causes the degeneration of the coating that protects nerves and a loss of white matter in the brain, according to Fox 6.
Typically, children suffering from the disease progressively lose the ability to move their muscles and effectively become locked in to their own bodies. Without treatment, most children with the disease die before the age of 10.
In 2003, when she was three years old, Fellenz underwent experimental surgery that saw a functional gene injected into her brain, with the hopes that it would displace the defective one. While it didn't cure her disease, it did buy her a decade's worth of life.
Dr Paola Leone, a professor of Cell Biology at Rowan University, requested that Fellenz's brain be preserved after her death, hoping that it could provide priceless data about both the disease and the body's response to her experimental treatment.
While 16 other children also received similar treatment, the circumstances of her death made her brain especially ideal for preservation.
According to Leone, most Canavan patients die in their homes, and their brain tissues degrade by the time they can be properly autopsied.
Fellenz, however, died at Children's Hospital Wisconsin, where doctors could work quickly to save her brain.
"The scenario was perfect," Leone told Fox 6. "She was in the hospital. The dry ice was there, ready to go."
Donating the brain was always the plan following her death, according to her parents, Scott and Arlo Fellenz.
'It was no question that we had to do that,' Scott said. 'It was a big part of her legacy.'
Unfortunately, the secrets of Fellenz's brain will never be uncovered.
When she died on December 5, officials at Children's Wisconsin decided that a previous donation consent form signed by her parents was out of date and that they would need to fill out another before the brain could be shipped to Living BioBank at the Children's Hospital in Dayton, Ohio.
Despite Leone providing Children's Wisconsin with the consent form, a month passed and the sample still hadn't been sent.
On January 13, more than a month after Fellenz's death, Dr Lauren Parsons, Director of Pathology at Children's Wisconsin, wrote an email to Leone thanking her for her "patience" and noting that "holidays and some leadership transitions" had kept the staff tied up, according to Fox 6.
Two more months passed without the brain being sent, Leone said, adding that many of her emails questioning the hold up were left unanswered.
Scott Fellenz told the broadcaster that Parsons "literally ghosted [Leone] for two months."
In March, Arlo Fellenz called the hospital demanding answers. Her call was returned from the hospital's "grief services" workers, who wanted to set up a meeting. She waved off the meeting and demanded they tell her what they needed to say over the phone.
The hospital then told the family they had accidentally 'disposed' of Fellenz's brain.
"They tossed out her brain. How can you do that with a brain?" Arlo said during an interview with Fox 6.
Half of Fellenz's brain did eventually get shipped to Ohio, but Leone was most interested in the information that the other half — the half that had not received the experimental injection — could reveal.
Fellenz's father said it felt like he had lost his daughter again. For Leone, the loss also represents a loss of potential knowledge that could have helped people suffering from gene conditions.
"This would have just led, just paved the way for any other application of gene therapy into the brain to let us know if gene therapy can persist," she told the broadcaster. "It's a loss of information that would have been precious and cited for the years to come, for the centuries to come, because this is the one and only specimen, not just for Canavan, for any other gene therapy,"
A spokesperson for Children's Wisconsin said they were 'profoundly sorry' for the error.
"We were honored to support Ashtyn's family's wish for her legacy to help others. As we communicated to the family when this error was discovered, and reiterate now, our team is profoundly sorry this happened, and we continue to take steps to reinforce our protocols to help ensure this does not occur again,' they said in a statement.
'The availability of human tissue to support life-changing and lifesaving medical research is critical to offering hope to families. We take seriously our work to support research through proper tissue collection, storage and usage. We are deeply grateful for Ashtyn's life and for her family's advocacy and care, and again offer our most sincere regret and apology."
When questioned further by Fox 6, the hospital said they have a 'comprehensive process' to manage donated tissue, aspects of which were 'not followed,' leading to the error.
The Fellenz family have now hired an attorney to represent them, and would use any money to help with Canavan research.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Ksana Health and Children's Wisconsin aim to improve paediatric mental health care
US-based digital mental health solution provider Ksana Health has partnered with Children's Wisconsin, a paediatric healthcare provider in Wisconsin, with the aim to improve the delivery of children's mental health care. The collaboration introduces Vira, a digital behavioural health care platform developed by Ksana Health using the Pediatric Primary Care Integrated Behavioral Health model. Vira uses artificial intelligence to support evidence-based therapeutic principles and includes smart automations to enhance clinical workflows. This aims to reduce the burden on healthcare providers and offer tailored mobile interventions to support children and their families' health. Children's Wisconsin Mental and Behavioral Health Research director Dr Michael Gaffrey said: "We see enormous potential in digital mental health tools to empower clinicians and families with continuous, data-driven behavioural support. "This collaboration marks a significant step forward in realising a sustainable, effective integration of mental health services within paediatric primary care." Ksana Health and Children's Wisconsin said the partnership underscores their focus on enhancing paediatric behavioural healthcare. The partners aim to emphasise accessibility, adherence to evidence-based practice, and the long-term sustainability of integrated mental health care. Ksana Health CEO Dr Nick Allen said: "Our goal is to revolutionise paediatric behavioural health by making effective, personalised interventions accessible precisely when youth and families need them. "Together, we're committed to addressing the mental health crisis facing today's youth with practical, scalable solutions that work." In paediatric primary care settings, where 90% of children are seen each year, there are significant opportunities for early identification and treatment of mental health issues. Despite this, many children with mental and behavioural health disorders do not receive the care they need. Addressing this gap has become a system-wide priority for Children's Wisconsin. The health system operates locations in Milwaukee and Neenah, Wisconsin, and claims to be recognised as one of the US' leading paediatric healthcare providers. "Ksana Health and Children's Wisconsin aim to improve paediatric mental health care" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 days ago
- Yahoo
Ksana Health and Children's Wisconsin aim to improve paediatric mental health care
US-based digital mental health solution provider Ksana Health has partnered with Children's Wisconsin, a paediatric healthcare provider in Wisconsin, with the aim to improve the delivery of children's mental health care. The collaboration introduces Vira, a digital behavioural health care platform developed by Ksana Health using the Pediatric Primary Care Integrated Behavioral Health model. Vira uses artificial intelligence to support evidence-based therapeutic principles and includes smart automations to enhance clinical workflows. This aims to reduce the burden on healthcare providers and offer tailored mobile interventions to support children and their families' health. Children's Wisconsin Mental and Behavioral Health Research director Dr Michael Gaffrey said: "We see enormous potential in digital mental health tools to empower clinicians and families with continuous, data-driven behavioural support. "This collaboration marks a significant step forward in realising a sustainable, effective integration of mental health services within paediatric primary care." Ksana Health and Children's Wisconsin said the partnership underscores their focus on enhancing paediatric behavioural healthcare. The partners aim to emphasise accessibility, adherence to evidence-based practice, and the long-term sustainability of integrated mental health care. Ksana Health CEO Dr Nick Allen said: "Our goal is to revolutionise paediatric behavioural health by making effective, personalised interventions accessible precisely when youth and families need them. "Together, we're committed to addressing the mental health crisis facing today's youth with practical, scalable solutions that work." In paediatric primary care settings, where 90% of children are seen each year, there are significant opportunities for early identification and treatment of mental health issues. Despite this, many children with mental and behavioural health disorders do not receive the care they need. Addressing this gap has become a system-wide priority for Children's Wisconsin. The health system operates locations in Milwaukee and Neenah, Wisconsin, and claims to be recognised as one of the US' leading paediatric healthcare providers. "Ksana Health and Children's Wisconsin aim to improve paediatric mental health care" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 days ago
- Yahoo
Increased Toxicity Risk Identified For Children With ADHD, Autism
The number of people being diagnosed with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) has risen sharply in recent decades, and research continues to look at factors involved in these conditions. A study published in 2023 revealed there's a difference in how children with autism or ADHD clear the common plastic compound bisphenol A (BPA), compared to neurotypical children. BPA is used in a lot of plastics and plastic production processes, and can also be found inside food and drink cans. However, previous research has also linked it to health issues involving hormone disruption, including breast cancer and infertility. Researchers from Rowan University and Rutgers University in the US looked at three groups of children: 66 with autism, 46 with ADHD, and 37 neurotypical kids. In particular, they analyzed the process of glucuronidation, a chemical process the body uses to clear out toxins within the blood through urine. They found that kids with ASD and ADHD couldn't clear out BPA and another similar compound called diethylhexyl phthalate (DEHP) with as much efficiency as other kids, potentially leading to longer exposure to their toxic effects. "Detoxification of these two plasticizers is compromised in children with ASD and ADHD," wrote the researchers in their published paper. "Consequently, their tissues are more exposed to these two plasticizers." It was only in the case of BPA that the difference was statistically significant though: the efficiency was reduced by about 11 percent for kids with ASD and 17 percent for kids with ADHD, compared with the control group of children. The researchers think that gene mutations in certain individuals mean that BPA can't be cleared as well as it needs to be, which means the substance sticks around in the body. That potentially could cause damage in terms of neuron development and operation. Conditions like ASD and ADHD are thought to involve a combination of genetic and environmental influences, and this new study brings together both of them. However, it's only part of the story – not every child with a neurodevelopmental disorder had problems flushing out BPA, so there are other factors at play, too. Work is continuing to identify how exactly ASD and ADHD develop in people – whether it's in utero before birth for example, or later on in life – as the data isn't enough to show whether BPA exposure causes either disorder. "There is an extensive body of epidemiological evidence for a relationship between neurodevelopmental disorders and environmental pollutants such as plasticizers," the researchers wrote. "How important plasticizer originated neurodevelopmental disorder is in the overall occurrence of these disorders is not known, but it must account for a significant proportion or would not have been so easy to detect in a metabolic study of moderate size such as this study." The research was published in PLOS ONE. A version of this article was first published in October 2023. Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover Texas Woman Dies From Brain-Eating Amoeba After Flushing Sinuses Menopause Drug Reduces Breast Cancer Growth In Clinical Trial